Precision medicine is steadily replacing healthcare’s old 'one-size-fits-all' playbook. Indeed by using genomic sequencing and protein biomarkers to understand a patient's specific condition, doctors can choose personalised therapies that improve efficacy and outcomes, while equally avoiding unnecessary treatment, toxicity and side effects.
Enter Verici Dx , whose kidney-transplant diagnostics already use multi-omic data and AI to help clinicians judge the risk of organ rejection and customise immunosuppression regimes.
Today the company added another potentially valuable income stream after becoming an Olink Certified Service Provider (part of Thermo Fisher's Life Sciences Solutions). In turn allowing its US laboratory to offer contract research (CRO) proteomics services for biomarker discovery, algorithm development, validation, clinical trials and diagnostics.
This is important because it not only creates a new fee-for-service revenue stream from pharma, biotech and other life-science customers, but also enhances the utilisation of its existing laboratory infrastructure.
What’s more, has already demonstrated this capability with a major pharmaceutical customer, analysing samples from a GLP-1 clinical trial using a custom protein panel.
COO Patti Connolly commenting: “Achieving Olink certification is an important milestone that reflects the strength of our laboratory team.”
In terms of the numbers, house broker Singer Capital Markets have a 1.3p/share target price based on FY26 revenue of $4.9m (+33%), including roughly $4.8m from c.2,100 Tutivia tests and $0.1m of services, gross profit of $3.5m, EBITDA of -$6.6m, PBT of -$7.4m and year-end net debt of around $0.1m.
The main headwind is cash burn (est $400k/month), albeit the June £2.6m gross fundraise at 0.35p/share, provides a cash runway to at least the end of 2026. In the FY’25 going concern statement, the Board recognised that #VRCI “will require additional capital before the end of 2026 and are taking steps to put in place such funding arrangements.”